



**BlueCross
BlueShield**

Federal Employee Program.

Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.85.040

Section:	Prescription Drugs	Effective Date:	January 1, 2025
Subsection:	Hematological Agents	Original Policy Date:	January 22, 2021
Subject:	Orladeyo	Page:	1 of 5

Last Review Date: December 13, 2024

Orladeyo

Description

Orladeyo (berotralstat)

Background

Orladeyo (berotralstat) is a plasma kallikrein inhibitor that binds plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with hereditary angioedema (HAE). In patients with HAE due to C1-inhibitor deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema attacks. Orladeyo decreases plasma kallikrein activity to control excess bradykinin generation in patients with HAE (1).

Regulatory Status

FDA-approved indication: Orladeyo is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older (1).

Limitations of use: Orladeyo should not be used for treatment of acute HAE attacks (1).

Additional doses or doses of Orladeyo higher than 150 mg once daily are not recommended. An increase in QT was observed at dosages higher than the recommended 150 mg once daily dosage and was concentration dependent (1).

Section:	Prescription Drugs	Effective Date:	January 1, 2025
Subsection:	Hematological Agents	Original Policy Date:	January 22, 2021
Subject:	Orladeyo	Page:	2 of 5

The safety and effectiveness of Orladeyo in pediatric patients less than 12 years of age have not been established (1).

Related policies

Beriner, Cinryze, Haegarda, Icatibant, Kalbitor, Ruconest, Takhzyro

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Orladeyo may be considered **medically necessary** if the conditions indicated below are met.

Orladeyo may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 12 years of age and older

Diagnosis

Patient must have the following:

1. Hereditary Angioedema (HAE) with **ONE** of the following:
 - a. Patient has a C1 inhibitor deficiency or dysfunction as confirmed by laboratory testing **AND ALL** of the following:
 - i. C4 level below the lower limit of normal as defined by the laboratory performing the test
 - ii. C1 inhibitor (C1-INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test **OR** normal C1-INH antigenic level and a low C1-INH functional level (functional C1-INH less than 50% or C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test)
 - b. Patient has normal C1 inhibitor as confirmed by laboratory testing **AND ONE** of the following:
 - i. F12, angiotensin-converting enzyme, plasminogen, or kininogen-1 (KNG1) gene mutation as confirmed by genetic testing
 - ii. Documented family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine (e.g.,

Section:	Prescription Drugs	Effective Date:	January 1, 2025
Subsection:	Hematological Agents	Original Policy Date:	January 22, 2021
Subject:	Orladeyo	Page:	3 of 5

cetirizine) for at least one month

AND ALL of the following:

1. Used for the routine prevention of hereditary angioedema attacks
2. **NO** dual therapy with other agents for the prevention of hereditary angioedema attacks (e.g., Cinryze, Haegarda, Takhzyro)
3. Inadequate treatment response or intolerance to a short-term course (5-days or less) of an androgen such as danazol, or a contraindication to one such as:
 - a. Undiagnosed abnormal genital bleeding
 - b. Markedly impaired hepatic, renal, or cardiac function
 - c. Pregnancy (member is currently pregnant or may become pregnant)
 - d. Breast feeding
 - e. Porphyria
 - f. Androgen-dependent tumor
 - g. Active thrombosis or history of thromboembolic disease
 - h. Prepubertal child

Prior – Approval *Renewal* Requirements

Age 12 years of age and older

Diagnosis

Patient must have the following:

Hereditary Angioedema (HAE)

AND ALL of the following:

1. Used for the routine prevention of hereditary angioedema attacks
2. Patient has experienced a significant reduction in frequency of hereditary angioedema attacks since starting treatment
3. **NO** dual therapy with other agents for the prevention of hereditary angioedema attacks (e.g., Cinryze, Haegarda, Takhzyro)

Policy Guidelines

Pre - PA Allowance

None

Section:	Prescription Drugs	Effective Date:	January 1, 2025
Subsection:	Hematological Agents	Original Policy Date:	January 22, 2021
Subject:	Orladeyo	Page:	4 of 5

Prior - Approval Limits

Quantity 84 capsules per 84 days

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Orladeyo (berotralstat) is a plasma kallikrein inhibitor that binds plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with hereditary angioedema (HAE). In patients with HAE due to C1-inhibitor deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema attacks. Orladeyo decreases plasma kallikrein activity to control excess bradykinin generation in patients with HAE (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Orladeyo while maintaining optimal therapeutic outcomes.

References

1. Orladeyo [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc.; November 2023.

Policy History

Date	Action
January 2021	Addition to PA
March 2021	Annual editorial review
April 2021	Added initiation requirements including C1 inhibitor testing, C4 testing, C1-INH testing, gene mutation testing, or documented family history of refractory angioedema and continuation requirement for significant reduction in frequency of HAE attacks since starting therapy per FEP
June 2021	Annual review
September 2022	Annual review and reference update

5.85.040

Section:	Prescription Drugs	Effective Date:	January 1, 2025
Subsection:	Hematological Agents	Original Policy Date:	January 22, 2021
Subject:	Orladeyo	Page:	5 of 5

September 2023	Annual review
December 2023	Annual review
September 2024	Annual review and reference update
December 2024	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 13, 2024 and is effective on January 1, 2025.